Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR.
Authors
Yu Sunakawa
Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan;
Yu Sunakawa , Hisateru Yasui , Manabu Shiozawa , Hiroyuki Takeda , Naoya Akazawa , Tamotsu Sagawa , Kazuhiro Shiraishi , Yoshihiro Okita , Hiroyuki Okuyama , Satoshi Yuki , Shoko Yanaka , Koutatsu Matsushima , Koki Miyakawa , Ayana Kobara , Wataru Ichikawa , Masashi Fujii , Akihito Tsuji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
UMIN000034885
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 177)
DOI
10.1200/JCO.2023.41.4_suppl.177
Abstract #
177
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
First Author: Marc Peeters
Poster
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
First Author: Nicola Normanno
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
First Author: Stefania Napolitano
Poster
2022 ASCO Annual Meeting
Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
First Author: Satoshi Yuki